Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure

Increased levels of intestinal VEGF are thought to worsen portal hypertension. The cause of the increase in the level of intestinal VEGF found during cirrhosis is not known. The aim of this study is to demonstrate a relationship between portal pressure (PP) and intestinal/ plasma VEGF levels in different stages of fibrosis/cirrhosis. In this experiment, rats were exposed to carbon tetrachloride (CCl4) for 6, 8 and 12 weeks. At the end of exposure, the three groups of rats exhibited three different stages of pathology: non‐cirrhotic, early fibrotic and cirrhotic, respectively. For those rats and their age‐matched controls, PP and intestinal/plasma VEGF levels were measured. Rats inhaling CCl4 for 12 weeks developed portal hypertension (18.02 ± 1.07 mmHg), while those exposed for 6 weeks (7.26 ± 0.58 mmHg) and for 8 weeks (8.55 ± 0.53 mmHg) did not. The rats exposed for 12 weeks also showed a 40% increase in the level of intestinal VEGF compared to the controls (P < 0.05), while those rats exposed to CCl4 inhalation for 6 and 8 weeks did not. There was a significant positive correlation between PP and intestinal VEGF levels (r2 = 0.4, P < 0.005). Plasma VEGF levels were significantly elevated in those rats exposed to 12 weeks of CCl4 inhalation (63.7 pg/ml, P < 0.01), compared to the controls (8.5 pg/ml). However, no correlation was observed between PP and plasma VEGF levels. It is concluded that portal pressure modulates intestinal VEGF levels during the development of cirrhosis.

[1]  V. Wacheck,et al.  Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[2]  M. Mitterhauser,et al.  Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. , 2009, Journal of hepatology.

[3]  M. Mejías,et al.  Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats , 2009, Hepatology.

[4]  M. Morales-Ruiz,et al.  Vascular endothelial growth factor and angiopoietin-2 play a major role in the pathogenesis of vascular leakage in cirrhotic rats , 2008, Gut.

[5]  R. Flisiak,et al.  Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: possible association with hepatic function impairment. , 2008, Cytokine.

[6]  Hiroki Takahashi,et al.  Interleukin-1alpha enhances angiogenesis and is associated with liver metastatic potential in human gastric cancer cell lines. , 2008, The Journal of surgical research.

[7]  A. Fowden,et al.  Localization and Control of Expression of VEGF-A and the VEGFR-2 Receptor in Fetal Sheep Intestines , 2008, Pediatric Research.

[8]  P. Carmeliet,et al.  Antiangiogenic treatment with Sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats , 2007, Hepatology.

[9]  M. Mejías,et al.  Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet‐derived growth factor blockade in rats , 2007, Hepatology.

[10]  R. Groszmann,et al.  Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers. , 2006, Journal of hepatology.

[11]  R. Groszmann,et al.  Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[12]  R. Groszmann,et al.  The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule , 2006, Hepatology.

[13]  J. Rodés,et al.  Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. , 2005, Journal of hepatology.

[14]  C. Rodríguez-Ramos,et al.  Implication of inflammation‐related cytokines in the natural history of liver cirrhosis , 2004, Liver international : official journal of the International Association for the Study of the Liver.

[15]  J. Rodés,et al.  Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. , 2004, Gastroenterology.

[16]  R. Groszmann,et al.  A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. , 2003, Journal of hepatology.

[17]  H. Yoshiji,et al.  Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis , 2003, Gut.

[18]  Werner Müller,et al.  Interleukin 6/gp130‐dependent pathways are protective during chronic liver diseases , 2003, Hepatology.

[19]  M. Suckow,et al.  Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model. , 2003, Carcinogenesis.

[20]  R. Groszmann,et al.  Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[21]  D. Wendum,et al.  Hypoxia‐induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis , 2002, Hepatology.

[22]  Christopher J. Robinson,et al.  The splice variants of vascular endothelial growth factor (VEGF) and their receptors. , 2001, Journal of cell science.

[23]  M. Sunday,et al.  Differential expression of VEGF isoforms in mouse during development and in the adult , 2001, Developmental dynamics : an official publication of the American Association of Anatomists.

[24]  G. Desideri,et al.  Circulating vascular endothelial growth factor levels are decreased in patients with chronic hepatitis and liver cirrhosis depending on the degree of hepatic damage. , 2000, Clinical science.

[25]  P. Carmeliet.  Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.

[26]  K. Matsushima,et al.  Attenuated liver fibrosis and depressed serum albumin levels in carbon tetrachloride‐treated IL‐6‐deficient mice , 1999, Journal of leukocyte biology.

[27]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[28]  E. Furth,et al.  Liver Failure and Defective Hepatocyte Regeneration in Interleukin-6-Deficient Mice , 1996, Science.

[29]  S. D. Lee,et al.  Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha, and hyperdynamic circulation. , 1996, Scandinavian journal of gastroenterology.

[30]  J. Park,et al.  The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. , 1993, Molecular biology of the cell.

[31]  C. Frelin,et al.  Expression of vascular endothelial growth factor by cultured endothelial cells from brain microvessels. , 1993, Biochemical and biophysical research communications.

[32]  K. Tanikawa,et al.  Serum Vascular Endothelial Growth Factor Levels in Various Liver Diseases , 2004, Digestive Diseases and Sciences.

[33]  Li-juan Zhang,et al.  Effects of cytokines on carbon tetrachloride-induced hepatic fibrogenesis in rats. , 2004, World journal of gastroenterology.

[34]  J. Winer,et al.  Aortic smooth muscle cells express and secrete vascular endothelial growth factor. , 1991, Growth factors.